Vertex Pharmaceuticals stock falls after pain drug fails in Phase 2 study
LONDON - Spreadex Ltd, a UK-based financial trading company, has altered its holdings in Xeros Technology Group PLC, according to a notification filed on May 9, 2025. The transaction, which crossed the threshold on May 8, 2025, resulted in Spreadex holding a combined total of 6.9883% of voting rights, both through direct shares and financial instruments such as Contracts for Difference (CFDs) and spread bets.
The notification, a regulatory requirement known as TR-1, indicates that Spreadex now directly holds 3.9505% of voting rights in Xeros Technology Group, with an additional 3.0378% through financial instruments. This brings Spreadex’s total number of voting rights in the company to 36,386,656.
Previously, Spreadex’s notification had shown a slightly higher percentage of direct voting rights at 4.0465%, but the recent change reflects a decrease in direct shareholding while maintaining the same level of voting rights through financial instruments.
Xeros Technology Group, listed on the London Stock Exchange (LON:LSEG) with the ISIN code GB00BMGYBJ57, is a UK issuer specializing in advanced water-saving technologies. The company’s shares are publicly traded and subject to market fluctuations based on investor activities and notifications such as this one.
Spreadex, established in 1999, is regulated by the Financial Conduct Authority (FCA) and offers trading opportunities in various global markets, including UK small caps. The company provides services that allow traders to speculate on the price movements of securities without necessarily owning the underlying assets.
The notification by Spreadex to Xeros Technology Group is a standard procedure that informs the market of significant changes in share ownership, ensuring transparency and regulatory compliance. This adjustment in holdings is part of the ongoing financial activities and does not necessarily indicate a strategic shift by Spreadex.
The information for this report is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.